A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia

Autor: Margaret T. Kasner, Molly B. Halloran, Jonathan Pan, Ellen K. Ritchie, Gerald J. Fetterly, Douglas Kramer, David G. Hangauer, James E. Thompson
Rok vydání: 2022
Předmět:
Zdroj: Investigational New Drugs. 40:773-781
ISSN: 1573-0646
0167-6997
DOI: 10.1007/s10637-022-01255-1
Popis: Background Poor tolerance to standard therapies and multi-drug resistance complicate treatment of elderly patients with acute myeloid leukemia (AML). It is therefore imperative to explore novel tolerable agents and target alternative pathways. KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymerization. Methods This multi-center phase Ib open-label safety and activity study involved elderly patients with relapsed or refractory AML, or who declined standard chemotherapy. Results Twenty-four patients averaging 74 years of age were enrolled. The majority previously received hypomethylating agents. Five doses were tested: 40 mg (n=1), 80 mg (n=2), 120 mg (n=8), 140 mg (n=12), and 160 mg (n=1). Seven patients were treated for 12 days or less, nine for 15-29 days, five for 33-58 days, and three for 77-165 days. One patient receiving 120 mg for 165 days had reduced splenomegaly and survived 373 days. Another had no evidence of disease progression for 154 days. One patient receiving 160 mg for 12 days remained treatment-free for about 18 months. Dose-limiting toxicities occurred in eight patients at: 120 mg (transaminitis, hyperbilirubinemia), 140 mg (mucositis, allergic reaction, transaminitis, acute kidney injury), and 160 mg (mucositis). The maximum tolerated dose for KX2-391 was 120 mg once daily. KX2-391 bone marrow concentrations were approximately similar to plasma concentrations. Conclusions This is the first study to evaluate the safety of KX2-391 in elderly patients with AML. Further studies are warranted, including alternative dosing phase I trials evaluating shorter courses at higher doses and phase II trials. Clinical Trial Registration: The study was registered at ClinicalTrials.gov: NCT01397799 (July 20, 2011).
Databáze: OpenAIRE
Externí odkaz: